Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 25.4 | 26.0 | 26.3 | 28.2 | 33.4 | 36.7 | 38.9 | 39.4 |
| Operating profit | $bn | 10.7 | 13.8 | ||||||
| Net profit | $bn | 7.3 | 5.9 | 6.6 | 6.7 | 4.1 | 7.7 | 9.4 | 12.7 |
| EPS reported | $ | 14.23 | 17.24 | ||||||
| Operating cashflow per share | $ | 18.51 | 22.25 | ||||||
| Capex per share | $ | 3.45 | 4.54 | ||||||
| FCF per share | $ | 15.06 | 17.71 | ||||||
| Free cash flow | $bn | 8.10 | 9.58 | ||||||
| Net debt | $bn | 45.5 | 40.8 | ||||||
| Book value equity | $bn | 8.7 | 14.4 | ||||||
| Book value per share | $ | 15.97 | 26.29 | ||||||
| Number of shares | m | 542 | 546 | ||||||
| DPS (TTM paid) | $ | 9.52 | 9.94 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 23.00 | 27.15 | ||||||
| P/B LTM | x | 20.34 | 17.64 | ||||||
| P/S LTM | x | 4.79 | 6.50 | ||||||
| P/FCF LTM | x | 21.74 | 26.43 | ||||||
| EV/EBITDA LTM | x | 13.11 | 16.18 | ||||||
| EV/Sales LTM | x | 6.03 | 7.55 | ||||||
| Earnings Yield LTM | % | 4.35% | 3.68% | ||||||
| FCF Yield | % | 4.60% | 3.78% | ||||||
| Quality | |||||||||
| ROE | % | 89.06% | 85.59% | ||||||
| ROIC | % | 13.16% | 15.63% | ||||||
| Operating margin | % | 29.06% | 35.53% | ||||||
| Gross margin | % | 70.80% | 73.97% | ||||||
| FCF/Sales | % | 22.05% | 24.61% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +88.23% | +33.23% | ||||||
| Sales Growth YoY | % | +9.92% | +8.27% | ||||||
| Net Income Growth YoY | % | +88.53% | +34.06% | ||||||
| FCF Growth | % | -22.07% | -16.97% | ||||||
| Operating Profit Growth | % | +47.09% | +59.74% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 2.91% | 2.12% | ||||||
| Dividend Growth | % | +5.78% | +5.86% | ||||||
| Payout Ratio | % | 66.44% | 57.19% | ||||||
| FCF/Debt | x | 0.15 | 0.18 | ||||||
| Net Debt/EBITDA | x | 2.69 | 2.25 | ||||||
| EBIT/Net interest | x | 3.88 | 5.25 | ||||||
| Net debt/market cap | % | 25.82% | 16.12% | ||||||
| Net debt/Equity | x | 5.25 | 2.84 | ||||||
| Gross debt/equity | x | 6.31 | 3.76 | ||||||
ETFs that hold Amgen
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Schwab U.S. Dividend Equity ETF | SCHD | 5 | 4.09% |
| State Street Health Care Select Sector SPDR ETF | XLV | 7 | 3.71% |
| State Street SPDR Dow Jones Industrial Average ETF Trust | DIA | 4 | 5.30% |
| Dimensional - US High Profitability ETF | DUHP | 10 | 1.78% |
| Vanguard Health Care ETF | VHT | 7 | 3.18% |
| iShares Biotechnology ETF | IBB | 2 | 8.36% |
| State Street SPDR S&P Biotech ETF | XBI | 3 | 1.79% |
| Amplify CWP Enhanced Dividend Income ETF | DIVO | 2 | 5.76% |
| iShares U.S. Healthcare ETF | IYH | 7 | 3.62% |
| iShares Global Healthcare ETF | IXJ | 10 | 2.80% |
Funds with Amgen among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Schwab U.S. Dividend Equity ETF | SCHD | 5 | 4.09% |
| State Street Health Care Select Sector SPDR ETF | XLV | 7 | 3.71% |
| State Street SPDR Dow Jones Industrial Average ETF Trust | DIA | 4 | 5.30% |
| Dimensional - US High Profitability ETF | DUHP | 10 | 1.78% |
| Vanguard Health Care ETF | VHT | 7 | 3.18% |
| iShares Biotechnology ETF | IBB | 2 | 8.36% |
| State Street SPDR S&P Biotech ETF | XBI | 3 | 1.79% |
| Amplify CWP Enhanced Dividend Income ETF | DIVO | 2 | 5.76% |
| iShares U.S. Healthcare ETF | IYH | 7 | 3.62% |
| iShares Global Healthcare ETF | IXJ | 10 | 2.80% |
Funds with Amgen among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free